WPI 2287 (Propafenone Hydrochloride Extended-Release 425 mg)
Pill with imprint WPI 2287 is White, Capsule-shape and has been identified as Propafenone Hydrochloride Extended-Release 425 mg. It is supplied by Actavis Pharma, Inc..
Propafenone is used in the treatment of atrial fibrillation; atrial flutter; wolff-parkinson-white syndrome; ventricular tachycardia and belongs to the drug class group I antiarrhythmics. Risk cannot be ruled out during pregnancy. Propafenone 425 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for WPI 2287
Propafenone Hydrochloride Extended-Release
- Imprint:
- WPI 2287
- Strength:
- 425 mg
- Color:
- White
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Group I antiarrhythmics
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Labeler / Supplier:
- Actavis Pharma, Inc.
- National Drug Code (NDC):
- 00591-2287
More about propafenone
- Propafenone Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 51 Reviews
- Drug class: group I antiarrhythmics
Consumer resources
- Propafenone
- Propafenone Tablets
- Propafenone Sustained-Release Capsules
- Propafenone (Advanced Reading)
Other brands: Rythmol, Rythmol SR
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
